Impax Laboratories Inc (NASDAQ:IPXL) – Equities researchers at Leerink Swann issued their FY2017 earnings per share estimates for Impax Laboratories in a note issued to investors on Tuesday. Leerink Swann analyst A. Fadia anticipates that the specialty pharmaceutical company will earn $0.65 per share for the year. Leerink Swann currently has a “Outperform” rating and a $22.00 target price on the stock. Leerink Swann also issued estimates for Impax Laboratories’ Q4 2017 earnings at $0.13 EPS, FY2018 earnings at $1.15 EPS, FY2019 earnings at $1.45 EPS, FY2020 earnings at $1.64 EPS and FY2021 earnings at $1.89 EPS.
Other analysts have also issued reports about the stock. Guggenheim began coverage on shares of Impax Laboratories in a research report on Tuesday, December 12th. They set a “neutral” rating and a $18.00 price target for the company. Canaccord Genuity set a $19.00 price target on shares of Impax Laboratories and gave the company a “hold” rating in a research report on Monday, December 18th. Cantor Fitzgerald set a $25.00 price target on shares of Impax Laboratories and gave the company a “buy” rating in a research report on Tuesday, October 17th. BTIG Research reissued a “buy” rating and set a $27.00 price target (up from $20.00) on shares of Impax Laboratories in a research report on Saturday, September 23rd. Finally, Goldman Sachs Group began coverage on shares of Impax Laboratories in a research report on Thursday, September 28th. They set a “neutral” rating and a $20.00 price target for the company. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $19.62.
Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.03. The company had revenue of $206.40 million during the quarter, compared to analyst estimates of $208.38 million. Impax Laboratories had a negative net margin of 56.59% and a positive return on equity of 9.06%. The firm’s revenue for the quarter was down 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.37 earnings per share.
Several institutional investors and hedge funds have recently bought and sold shares of IPXL. Rhumbline Advisers increased its holdings in shares of Impax Laboratories by 5.1% during the second quarter. Rhumbline Advisers now owns 152,717 shares of the specialty pharmaceutical company’s stock valued at $2,459,000 after acquiring an additional 7,393 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Impax Laboratories during the second quarter valued at about $572,000. Legal & General Group Plc increased its holdings in shares of Impax Laboratories by 8.1% during the second quarter. Legal & General Group Plc now owns 142,452 shares of the specialty pharmaceutical company’s stock valued at $2,292,000 after acquiring an additional 10,618 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Impax Laboratories by 56.4% during the second quarter. BNP Paribas Arbitrage SA now owns 23,498 shares of the specialty pharmaceutical company’s stock valued at $378,000 after acquiring an additional 8,469 shares in the last quarter. Finally, Swiss National Bank increased its holdings in shares of Impax Laboratories by 15.3% during the second quarter. Swiss National Bank now owns 116,900 shares of the specialty pharmaceutical company’s stock valued at $1,882,000 after acquiring an additional 15,500 shares in the last quarter. Hedge funds and other institutional investors own 90.48% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Research Analysts Offer Predictions for Impax Laboratories Inc’s FY2017 Earnings (IPXL)” was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.com-unik.info/2018/01/07/research-analysts-offer-predictions-for-impax-laboratories-incs-fy2017-earnings-ipxl.html.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
What are top analysts saying about Impax Laboratories? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Impax Laboratories and related companies.